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Abstract
Bleeding is the most important complication of oral an-
ticoagulation (OAC) with vitamin K-antagonists. Whilst 
bleeding is unavoidably related to OAC, it may have a 
great impact on the prognosis of treated subjects by 
leading to discontinuation of treatment, permanent dis-
ability or death. The yearly incidence of bleeding during 
OAC is 2%-5% for major bleeding, 0.5%-1% for fatal 
bleeding, and 0.2%-0.4% for intracranial bleeding. 
While OAC interruption and/or antagonism, as well as 
administration of coagulation factors, represent the 
necessary measures for the management of bleeding, 
proper stratification of the individual risk of bleeding 
prior to start OAC is of paramount importance. Several 
factors, including advanced age, female gender, poor 
control and higher intensity of OAC, associated dis-
eases and medications, as well as genetic factors, have 
been proven to be associated with an increased risk of 
bleeding. Most of these factors have been included in 
the development of bleeding prediction scores, which 
should now be used by clinicians when prescribing 
and monitoring OAC. Owing to the many limitations of 
OAC, including a narrow therapeutic window, cumber-
some management, and wide inter- and intra-individual 
variability, novel oral anticoagulants, such as factor Xa 
inhibitors and direct thrombin inhibitors, have been 
recently developed. These agents can be given in fixed 
doses, have little interaction with foods and drugs, and 
do not require regular monitoring of anticoagulation. 
While the novel oral anticoagulants show promise for 
effective thromboprophylaxis in atrial fibrillation and ve-
nous thromboembolism, definitive data on their safety 
and efficacy are awaited.
© 2011 Baishideng. All rights reserved.
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INTRODUCTION
The purpose of  oral anticoagulation (OAC) therapy is 
to induce a controlled depression of  blood coagulability 
in order to reduce the risk of  thromboembolic compli-
cations in clinical conditions such as atrial fibrillation, 
mechanical heart valves, deep vein thrombosis and pul-
monary embolism, and cardiogenic stroke. While newer 
oral anticoagulants, such as direct thrombin inhibitors (i.e., 
dabigatran) and direct factor Xa inhibitors (i.e., apixaban, 
rivaroxaban), have been recently evaluated in the clinical 
setting[1-5], vitamin K antagonists (VKAs), such as warfa-
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rin, acenocoumarol, and phenprocoumon, currently rep-
resent the standard drugs for OAC therapy.
The anticoagulant effect of  VKAs is a consequence 
of  their interference with the cyclic interconversion of  
vitamin K and its epoxide, by means of  the inhibition 
of  the vitamin K epoxide reductase enzyme (VKORC1), 
which in turn, is essential for the gamma-carboxylation 
of  vitamin K-dependent coagulation factors, including 
factor Ⅱ, Ⅶ, Ⅸ and Ⅹ[6] (Figure 1). While acenocouma-
rol and phenprocoumon are preferred in some countries, 
warfarin is the VKA most commonly used in clinical 
practice[6]. Warfarin is a racemic mixture of  two optically 
active isomers, the R and S enantiomers[6]. It is rapidly 
absorbed from the gastrointestinal tract, has high bio-
availability, and reaches its maximal blood concentration 
about 90 min after oral administration[6]. Racemic warfa-
rin has a half-life of  36-42 h, as compared to 8-24 h for 
acenocoumarol, and 80-270 h for phenprocoumon, cir-
culates bound to plasma proteins, and accumulates in the 
liver, where the two enantiomers are metabolized by dif-
ferent pathways[6]. The S enantiomer, which is about three 
times more potent than the R enantiomer, is primarily 
metabolized by the CYP2C9 enzyme of  the cytochrome 
P450 system, whereas the R enantiomer is metabolized 
by the CYP1A2 and CYP3A4 enzymes[6].
In order to maximize protection against thromboem-
bolic complications while minimizing the risk of  bleed-
ing associated with VKA therapy, the intensity of  OAC 
should be maintained within a narrow therapeutic range 
(TTR). Apart from non-bileaflet mechanical heart valves 
and mechanical heart valves in the mitral position, where 
a higher intensity of  OAC therapy is required, an inter-
national normalized ratio (INR) of  2.0-3.0 has long been 
identified as the optimal TTR for most clinical conditions 
at risk for thromboembolic events[6]. Nonetheless, bleed-
ing represents the major complication of  OAC therapy, 
even when OAC is properly prescribed[7].
INCIDENCE OF BLEEDING
The reported incidence of  bleeding during OAC therapy 
with VKAs is highly variable in published studies. This 
variability may be accounted for by the differences in the 
definition and classification of  bleeding (Table 1). More 
importantly however, the differences in the reported 
hemorrhagic rates are more likely to be attributed to 
differences in study design and patient population. In 
randomized clinical trials, where highly selected patients 
are enrolled, rates of  bleeding are expected to be lower 
than in observational studies, where patients commonly 
encountered in clinical practice, including those with 
individual risk factors for bleeding, are included. As an 
example, in six pivotal trials evaluating the effect of  war-
farin compared to placebo in patients with atrial fibril-
lation, only 12.6% out of  the 28 787 patients screened 
were finally included[8]. Whether or not monitoring of  
OAC therapy is carried out in specialized services, where 
a better and more stable control of  the INR is generally 
achieved, may also have an impact on the occurrence of  
bleeding complications[9].
The expected incidence of  bleeding during long-term 
VKA therapy is about 10%-17% per year for all events, 
2%-5% per year for major bleeding, and 0.5%-1% per 
year for fatal bleeding[10]. The reported occurrence of  
intracranial hemorrhage (ICH), which represents the 
mostly feared bleeding complication of  VKA therapy 
because of  its high disability and/or fatality rate, is in the 
range of  0.2%-0.4% per year[7,11]. 
CLINICAL IMPACT AND MANAGEMENT 
OF BLEEDING
The occurrence of  bleeding during OAC therapy with 
VKAs has relevant prognostic and management impli-
cations. Major bleeding can be life-threatening, such as 
when occurring at critical sites like the head, the pericar-
dium or the pleura, or when leading to the development 
of  hemorrhagic shock. Also, major bleeding complica-
tions are generally associated with VKA discontinua-
tion, which in turn, contributes to adverse outcomes 
by leaving the patient exposed to an increased risk of  
thromboembolism. In a recent meta-analysis of  clinical 
trials reporting on OAC therapy with VKAs for venous 
thromboembolism, a case-fatality rate of  major bleeding 
of  13.4% (95% CI: 9.4%-17.4%) has been reported in 
all patients, with a rate of  ICH of  1.15% per year (95% 
CI: 2.5%-21.7%)[12]. Regardless of  the severity however, 
hemorrhagic complications of  OAC therapy with VKAs 
may be important for the related inconvenience to the 
patients. The perceived higher risk of  bleeding of  VKA 
therapy limits its more widespread use, therefore exclud-
ing many patients from the benefits of  such therapy. It 
has been shown that the occurrence of  VKA-associated 
adverse events has an impact on the prescribing of  this 
treatment, since physicians are less likely to prescribe 
VKAs after observing a bleeding complication during 
VKA treatment in their patients[13].
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Figure 1  Mechanism of action and metabolism of warfarin. VKORC1: Vita-
min K epoxide reductase enzyme.
Management of  bleeding occurring during OAC 
therapy with VKAs generally consists of  discontinuation 
and/or antagonism of  VKAs, as well as of  local mea-
sures (i.e. endoscopic treatment and/or surgical hemosta-
sis) and proper transfusion procedures. Discontinuation 
of  VKAs allows for subsequent normalization of  INR, 
which may require several hours owing to the prolonged 
half-life of  VKAs. According to available data, tempo-
rary interruption of  VKA therapy because of  major 
bleeding or trauma appears not to be associated with an 
increased risk of  subsequent thromboembolic complica-
tions[14,15]. In a population of  28 patients with prosthetic 
heart valves receiving warfarin and hospitalized for major 
hemorrhage who were retrospectively evaluated, discon-
tinuation of  OAC therapy for 1 d to > 3 wk (mean dura-
tion 15 ± 4 d) was not associated with thromboembolic 
complications at 6-mo follow-up[14]. In a retrospective, 
population-based, cohort study evaluating 8450 patients 
aged > 65 years on warfarin for various reasons and sur-
viving a major trauma, the incidence of  stroke at a mean 
follow-up of  3.3 years did not differ between patients 
who discontinued warfarin as compared to those who 
continued warfarin [hazard ratio (HR), 0.99; 95% CI: 
0.82-1.21], while the incidence of  major hemorrhages 
was significantly lower (HR, 0.69; 95% CI: 0.54-0.88) 
and that of  venous thromboembolism was significantly 
higher (HR, 1.59; 95% CI: 1.07-2.36)[15]. Antagonism of  
the VKA anticoagulation effect is obtained by directly 
administering vitamin K[16]. Vitamin K can be given orally 
or intravenously, with the parenteral route having the 
advantage of  a more rapid onset of  action[17]. After intra-
venous administration of  vitamin K, the INR will start to 
drop within 2 h and will be normalized within 12-16 h[18], 
whereas after oral administration it will take up to 24 h to 
normalize the INR[19]. While low (1-2.5 mg) to moderate 
(2.5-5 mg) doses of  vitamin K given orally are indicated 
for the management of  non-emergency bleeding, slow 
intravenous infusion of  10 mg vitamin K should be given 
in emergency situations[6]. Higher doses of  vitamin K are 
equally effective but may induce resistance to VKAs for 
more than 1 wk[20], and are therefore not recommended. 
In emergency situations, immediate correction of  high 
INR should be pursued also by the administration of  vi-
tamin K-dependent coagulation factors. These factors are 
present in fresh frozen plasma, which however is incon-
venient to use owing to the very large amount needed, 
the prolonged time required for administration, and the 
associated risk of  fluid overload[21]. Therefore, prothrom-
bin complex concentrates, most of  which contain all vi-
tamin K-dependent coagulation factors, are more useful 
and should be administered either according to fixed dose 
schemes or, preferably, by individualized dosing regimens 
based on INR value and body weight[22]. 
RISK FACTORS FOR BLEEDING
Numerous factors, including individual characteristics, 
intensity, timing and quality of  OAC therapy, and use 
of  concomitant medications, have been established as 
impacting on the risk of  bleeding during VKA treatment 
(Table 2).
Age
In most studies, older age has consistently shown to in-
crease the risk of  bleeding[11]. As compared to younger 
patients, elderly patients have about a 5-fold higher in-
cidence of  major and fatal bleeding (3.2% and 0.64% 
per year vs 0.6% and 0.12% per year, respectively)[23]. 
Importantly, the risk of  ICH is particularly increased in 
subjects of  advanced age[24]. In patients aged ≥ 85 years 
an adjusted odds ratio of  2.5 (95% CI: 2.3-9.4) for ICH 
has been recently reported in comparison to a reference 
group of  patients of  70-74 years[25]. Elderly patients are 
at higher risk of  bleeding for several reasons, including 
the lower dose of  anticoagulant required for effective an-
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Table 1  Different definitions of major bleeding in various studies
Ref. Clinical setting Definition
Landefeld et al[53] Various Fatal, life-threatening, potentially life-threatening, causing severe blood loss, leading to surgical treatment or 
moderate acute/subacute blood loss not explained by surgery/trauma
Palareti et al[32] Various Fatal intracranial (documented by imaging); ocular (with blindness); articular; retroperitoneal; requiring 
surgery/angiographic intervention; associated to Hb decrease ≥ 2 g/dL or need for ≥ 2 blood units transfusion
Beyth et al[54] Various Overt bleeding leading to ≥ 2 blood units loss in ≤ 7 d, or life-threatening
Gage et al[55] AF ICD-9CM codes for bleed in any location
Shireman et al[56] AF Hospitalization for “major acute bleeding” (including gastrointestinal or intracranial hemorrhage)
AF: Atrial fibrillation; Hb: Hemoglobin.
Table 2  Factors associated with an increased risk of bleeding
Author
Age > 65-70 yr
Female gender
CYP2C9 and/or VKORC1 gene polymorphism
Higher intensity of anticoagulation (i.e., INR > 4.5)
Labile INR (i.e., TTR < 60%)
Early 90 d of anticoagulation
History of bleeding
Comorbidities (i.e., hypertension, malignancy, liver and/or renal and/
or cardiac failure)
Comedications (i.e., antiplatelet agents, non-steroidal anti-inflammatory 
drugs)
INR: International normalized ratio; TTR: Time within the therapeutic 
range.
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ticoagulation (mainly because of  reduced metabolic clear-
ance)[26], the higher frequency of  pathological changes 
in cerebral vessels, such as leukoaraiosis and amyloid 
angiopathy, which may increase the risk of  ICH[27,28], and 
the increased prevalence of  diverticulosis, malignancy, an-
giodysplasias, and ischemic colitis, which in turn may pre-
dispose to gastrointestinal bleeding. Additionally, elderly 
patients have a higher prevalence of  comorbid conditions 
and are more likely to take interacting drugs[29]. Non-
compliance to VKAs and lack of  a clear understanding 
of  their purpose and actions by older patients[30], who are 
also prone to mental impairment, are additional factors 
which may influence the bleeding rate.
Gender
Female gender has been found to be associated with a 
greater risk of  bleeding during OAC therapy with VKAs 
for atrial fibrillation[31,32], but such an association has not 
been found in another study which enrolled patients with 
various indications for VKA anticoagulation[33]. 
Intensity and quality of anticoagulation
Although bleeding complications are not always related 
to a high intensity of  anticoagulation and may occur even 
with INR values lower than 2.0, the target intensity of  
anticoagulation, and especially the actually achieved in-
tensity, have long been recognized as major determinants 
of  anticoagulation-related hemorrhages[11]. The increase 
in bleeding becomes exponential for INR values > 4.5, 
while the lowest rate is observed with INR values be-
tween 2.0 and 3.0[32]. The risk of  death is also related to 
INR values with a minimum risk at INR 2.2[34]. High INR 
values are associated with an excess in mortality as well 
with a 2-fold increase in risk for one unit increase in INR 
above 2.5[34].
The initiation phase of  anticoagulation, and especially 
the first 90 d of  treatment, are associated with a higher 
incidence of  bleeding[32,35]. Factors including the unmask-
ing of  occult lesions at the beginning of  anticoagulation 
and/or less adequacy of  dose adjustments in that period 
may account for this finding.
The quality of  anticoagulation, as expressed by the 
time spent within the TTR, is another important variable 
influencing the likelihood of  hemorrhagic complications. 
A strong relationship between TTR and bleeding, as well 
as thromboembolic complications, has consistently been 
reported in different patient populations and different 
intensity ranges[6]. Both major bleeding and mortality 
rates have been reported to be significantly higher in pa-
tients with TTR < 60% (3.85% and 4.20%, respectively) 
compared to those with TTR > 75% (1.58% and 1.69%, 
respectively)[36]. Apart from the application of  general 
measures, like patient information and education and use 
of  coumarin derivatives with a longer half-life, such as 
warfarin and phenprocoumon[37-39], achievement of  good 
anticoagulation control may be better obtained by moni-
toring the treatment at specialized coagulation services or 
by patients themselves[6,40]. 
Comorbid conditions and comedications
Both as a marker of  increased patient frailty and cause 
of  concomitant use of  other medications, the presence 
of  comorbidities represents another factor potentially 
increasing the risk of  bleeding during OAC therapy with 
VKAs. Apart from previous bleeding (especially in the 
gastrointestinal tract), which is the most potent predic-
tor of  recurrent hemorrhagic complications, congestive 
heart failure, hepatic or renal failure and diabetes have 
been identified as conditions associated with major bleed-
ing[41,42]. Blood pressure control is also a critical factor 
for hemorrhagic complications during VKAs therapy. 
Among anticoagulated patients experiencing bleeding 
complications, a higher prevalence of  history of  hy-
pertension has been frequently reported compared to 
patients with no previous bleeding[43]. Therefore, strict 
monitoring and control of  blood pressure is warranted 
to reduce the risk of  major hemorrhagic complications. 
More time spent above the intended intensity of  OAC 
and wide and unpredictable fluctuations of  the INR 
have been observed in patients with malignancies, which 
should also be regarded as risk factors for bleeding dur-
ing VKA anticoagulation[44]. 
Among concomitant drugs frequently taken by pa-
tients on OAC therapy, antiplatelet agents are the most 
important because of  the additional inhibitory effect 
on the anticoagulation system. Such an effect is of  high 
clinical relevance because of  the frequent coexistence, 
especially in elderly patients, of  conditions such as atrial 
fibrillation or venous thromboembolism and coronary ar-
tery disease, where both VKAs and antiplatelet agents are 
indicated. Indeed, a relative risk of  major bleeding of  2.5 
(95% CI: 1.7-3.7) has been reported for the association of  
VKAs and aspirin[45]. An increasingly important subset of  
OAC patients potentially at increased bleeding risk is rep-
resented by those with an acute coronary syndrome and/
or undergoing percutaneous coronary intervention with 
stent implantation, in whom a course of  dual antiplatelet 
therapy with aspirin and clopidogrel is necessary to pre-
vent stent thrombosis and/or ischemic recurrences. These 
patients represent 5%-10% of  the whole population 
undergoing percutaneous coronary revascularization and 
appear exposed to a higher risk of  major bleeding, which 
apparently increases with prolongation of  treatment[46,47]. 
While waiting for solid data on drug combinations, such 
as VKAs plus clopidogrel[48], in patients on triple therapy 
of  VKA, aspirin and clopidogrel, meticulous care should 
be exerted (1) to prolong this regimen for as short as pos-
sible (therefore avoiding the implantation of  drug-eluting 
stents for which a duration of  6-12 mo of  clopidogrel 
therapy is recommended)[49]; (2) to target an INR at the 
lower end (i.e., between 2.0 and 2.5) of  the TTR; (3) to 
frequently review the patient and test the INR; and (4) to 
extensively use gastric protective agents[46,47]. 
Genetic factors
Recent advances in the pharmacogenetics of  VKAs have 
greatly increased the understanding of  their mechanism 
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of  action and of  the known broad inter-individual vari-
ability in VKA response. It is now known that at least 
30 genes are involved in the metabolism and action of  
warfarin, and some polymorphism of  genes encoding for 
VKORC1 and CYP2C9 enzymes is present[6,50]. While 
mutations of  VKORC1 are associated with different sen-
sitivities to VKA, polymorphism of  CYP2C9 can cause 
a delayed stabilization of  VKA treatment[11]. Indeed, CY-
P2C9 variants are significantly more frequent among pa-
tients with an unstable response to VKAs[30] who achieve 
a stable dose significantly later, spend significantly more 
time above the therapeutic INR range in the initial phase 
of  treatment, and have higher risk of  having INR values 
> 5.0 as compared to non-carrier patients[50]. Owing to 
the reported association between gene variants and risk 
of  bleeding and dose requirements in the initial phase 
of  anticoagulation[51], several dosing algorithms based on 
VKORC1 and CYP2C9 genotypes have been proposed, 
although not integrated yet in clinical practice, to assist 
initiation of  VKA treatment[52]. 
BLEEDING RISK SCORES
Stratification of  the individual bleeding risk prior to ini-
tiation of  OAC therapy with VKAs is another important 
measure to adopt for prevention of  hemorrhagic compli-
cations[53]. To assist clinicians in this task, several schemes 
have been developed (Table 3).
The modified outpatient bleeding risk index (mOBRI) 
has been prospectively derived and extensively validated 
in patients with different indications for VKAs[54]. Also, 
the mOBRI was evaluated in a “real-life” setting of  an-
ticoagulation monitoring (i.e., primary care physicians or 
pharmacist-run anticoagulation clinic) and the assessment 
of  bleeding was blinded[54]. The hepatic or renal disease, 
ethanol abuse, malignancy, older, reduced platelet count/
function, re-bleeding, uncontrolled hypertension, anemia, 
genetic factors, excessive fall risk, and stroke score has 
been derived from a retrospective chart review of  na-
tionwide registry data of  patients with atrial fibrillation[55]. 
The retrospective design, the inclusion of  genetic factors 
(which are rarely investigated in common practice), and 
of  anemia and platelet data (also infrequently available), 
limit the usefulness of  this score, as well as the lack of  in-
clusion of  important factors such as the concomitant use 
of  antiplatelet agents and/or other drugs. The schema 
by Shireman et al[56] is also derived from a retrospective 
evaluation of  nationwide registry data, and incorporates 
eight risk factors for bleeding. As regards limitations, the 
follow-up period was relatively short (i.e. 90 d), the out-
come assessment was not blinded, and the quality of  an-
ticoagulation control and the use of  comedications were 
not reported[56]. Finally, the individual determination of  
this score requires a complex mathematical calculation, 
which makes it rather impractical[56]. The hypertension, 
abnormal liver or renal function, stroke, bleeding, labile 
INRs, elderly, drugs or alcohol (HAS-BLED) score has 
been recently developed for patients with atrial fibril-
lation, based on the prospective Euro Heart Survey on 
atrial fibrillation[57]. Compared with the previous three 
scores, the HAS-BLED score was recently demonstrated 
to have better predictive ability for bleeding among all pa-
tients enrolled in the SPORTIF Ⅲ and Ⅴ trials, as well as 
among warfarin-naïve patients and patients treated with 
warfarin and aspirin[58]. The HAS-BLED score appears 
easy and user-friendly for everyday application, owing to 
the small number of  variables to memorize and the com-
mon availability of  all the information required for risk 
calculation. Finally, the HAS-BLED score allows for peri-
odical re-assessment of  a patient’s bleeding risk as it also 
takes into account the quality of  INR control.
When applying the different bleeding scores, a wide 
variability in the prevalence of  patients determined to be 
at low-, moderate-, and high-risk is observed because of  
differences in the risk factors comprising each schema, 
the various definitions of  major bleeding, the different 
lengths of  follow-up in the cohorts, and the different 
populations evaluated in the studies. Furthermore, no 
data on the impact of  these scores on patient outcomes 
are currently available, so that none of  the proposed 
bleeding risk scores can currently be recommended for 
widespread clinical use. Nonetheless, it must be empha-
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Table 3  Most popular bleeding risk prediction scores
Author Ref. Calculation Risk classification 
mOBRI [54] Age ≥ 65 yr, previous stroke, GI bleed in the last 2 wk, ≥ 1 of the following: recent MI, 
hematocrit < 30%, creatinine > 1.5 mg/dL, diabetes)
Low: 0 points
Intermediate: 1-2 points
1 point each High: ≥ 3 points
HEMORR2HAGES [55] Hepatic or renal disease, ethanol abuse, malignancy, older, reduced platelet count/function, 
re-bleeding, uncontrolled hypertension, anemia, genetic factors, excessive fall risk, and stroke
Low: 0-1 points
Intermediate: 2-3 points
1 point each and 2 points for previous bleed High: ≥ 4 points
Shireman et al [56] (0.49 × age ≥ 70 yr) + (0.32 × female gender) + (0.58 × remote bleed) + (0.62 × recent bleed) 
+ (0.71 × alcohol/drug abuse) + (0.27 × diabetes) + (0.86 × anemia) + (0.32 × antiplatelet 
therapy)
 Low: ≤ 1.07 points
Intermediate: < 1.07 to 
< 2.19 points
1 point each High: ≥ 2.19 points
HAS-BLED [57] Hypertension (SBP > 160 mmHg), abnormal renal/liver function, stroke, history of bleeding, 
labile INR, elderly age (> 65 yr), drugs (antiplatelets/NSAIDs/alcohol)
Low: 0-1 points
Intermediate: 1-2 points
1 point each High: ≥ 3 points
GI: Gastrointestinal; MI: Myocardial infarction; SBP: Systolic blood pressure; NSAIDs: Non-steroidal antiinflammatory drugs.
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sized that bleeding risk stratification should represent an 
integral part of  the management of  OAC therapy, and 
application of  these scores may assist clinicians in their 
decision-making in everyday clinical practice.
NOVEL ORAL ANTICOAGULANTS
While VKAs are the standard drugs for OAC therapy, 
they have several major limitations, including the narrow 
therapeutic window, the cumbersome management, and 
the wide inter- and intra-individual variability. Therefore, 
more effective and/or safer and/or easier to use oral an-
ticoagulants have long been sought. Recently, two main 
classes of  new non-VKA oral anticoagulants (i.e. factor 
Xa-inhibitors and direct thrombin inhibitors) have been 
developed. These agents can be given in fixed doses, have 
little interaction with foods and drugs, and do not require 
regular monitoring of  anticoagulation[59]. 
Apixaban, rivaroxaban and edoxaban are orally ac-
tive, direct inhibitors of  factor Xa. While being currently 
evaluated in several large, double-blind trials in patients 
with atrial fibrillation or venous thromboembolism, some 
evidence about the efficacy and safety of  these drugs 
has already been reported. In the EINSTEIN-DVT and 
EINSTEIN-Extension studies[1], 3449 patients with acute 
deep vein thrombosis received, in an open-label manner, 
rivaroxaban or standard treatment (i.e. initial course of  
enoxaparin followed by VKAs) for 3, 6 or 12 mo. The 
602 patients who had completed 6 to 12 mo of  treatment 
then entered a double-blind study with randomization 
to rivaroxaban or placebo for an additional 6 or 12 mo. 
In the whole population, the efficacy of  rivaroxaban on 
recurrent venous thromboembolism was non-inferior to 
the enoxaparin/VKA regimen (2.1% vs 3.0%, P < 0.001). 
The safety, as expressed by the on-treatment occurrence 
of  major bleeding, was identical (8.1% in both groups). 
In the extended-treatment group, rivaroxaban was signifi-
cantly more effective (1.3% vs 7.1%, P < 0.001), however, 
there was an increased, albeit non significant, incidence 
of  major bleeding (0.7% vs 0%). In the AVERROES 
trial[2] 5599 patients with atrial fibrillation, who were 
unsuitable for or who were not willing to receive VKAs 
were randomized to apixaban or aspirin. At the 1.1-year 
follow-up, the treatment with apixaban was significantly 
more effective on the incidence of  stroke/systemic 
embolism (1.6% vs 3.7%, P < 0.001). No differences in 
the rates of  major bleeding were observed between the 
apixaban and aspirin groups (1.4% vs 1.2%, P = 0.57). In 
the double-blind ROCKET-AF trial[3], which enrolled > 
14 000 atrial fibrillation patients, and investigated the effi-
cacy (incidence of  stroke/systemic embolism) and safety 
(incidence of  bleeding) of  rivaroxaban compared to war-
farin, rivaroxaban was more effective (1.71% vs 2.16%, P 
< 0.001 for non-inferiority), without no significant differ-
ence in the rate of  major bleeding (3.60% vs 3.45%). 
Dabigatran is an orally active, direct thrombin inhibi-
tor, which has been tested for the long-term treatment 
of  patients with nonvalvular atrial fibrillation and venous 
thromboembolism. In the RE-LY trial, 18 113 patients 
with atrial fibrillation were randomized to two blinded 
doses of  dabigatran against open-label warfarin[4]. At 
2-year follow up, the primary outcome of  stroke and sys-
temic embolism was lower both with low-dose and high-
dose dabigatran compared to warfarin (1.53% and 1.11% 
vs 1.69%, P < 0.001 for non-inferiority and P < 0.001 for 
superiority, respectively). The incidence of  major bleed-
ing was lower in the low-dose group (2.71% vs 3.36%, P 
= 0.03) and similar to warfarin in the high-dose group 
(3.11% vs 3.36%, P = 0.31). Among the 2564 patients 
with acute venous thromboembolism enrolled in the 
double-blind RE-COVER study, dabigatran was as ef-
fective as warfarin for secondary prevention of  recurrent 
venous thromboembolism at 6-mo follow-up (2.4% vs 
2.1%). The incidence of  major bleeding was also compa-
rable in the two groups (1.6% vs 1.9%)[5]. 
In the light of  the promising outcomes, as well as of  
the superior ease of  use, the novel non-VKA oral antico-
agulants represent an attractive alternative to VKAs for 
OAC therapy. Nonetheless, additional data on the impact 
of  the lack of  a method to monitor the intensity of  anti-
coagulation, lack of  a specific antidote, and little informa-
tion regarding the risk/benefit ratio of  their combination 
with more potent antiplatelet agents, such as the increas-
ingly used prasugrel or ticagrelor, are necessarily awaited 
before these drugs can be truly considered substitutes for 
VKAs. 
CONCLUSION
OAC therapy with VKAs is the most effective available 
treatment for prevention of  thromboembolic complica-
tions in frequent clinical conditions, such as atrial fibrilla-
tion, venous thromboembolism, prosthetic heart valves, 
and cardiogenic stroke. Such efficacy comes at the price 
of  an increased risk of  overall, major and ICH bleeding. 
While novel, non-VKA oral anticoagulants, such as direct 
thrombin inhibitors and direct factor Xa inhibitors, have 
been showing promise in the setting of  atrial fibrillation 
and venous thromboembolism, VKA treatment should 
currently be offered to all patients at high risk of  arterial/
venous thromboembolism because of  the established 
benefit outweighing the risk. However, meticulous care 
should be directed towards accurate bleeding risk stratifi-
cation and minimization and/or control of  all the numer-
ous factors known to influence the risk of  hemorrhagic 
complications.
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